FILANA THERAPEUTICS, INC. (FLNA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board –Appointment brings leadership experience building and financing biopharma companies AUSTIN, Texas, November 11, 2026 (GLOBE NEWSWIRE) –– Filana Therapeutics, Inc. (NASDAQ: FLNA), a biotechnology

Event · Exec change
Person
Jill M. Quigley
Title
Independent Director
Action
appointed

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 12, 2026, 1:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 1:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$FLNA
Neutral
medium confidence
Mentioned
$FLNA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$FLNANeutralLow
01

Why it matters

The appointment signals governance strengthening ahead of a pivotal trial, but no immediate financial or operational change.

02

Market read

Limited to FLNA shareholders; no sector‑wide catalyst.

03

What to watch

Potential dilution risk if new financing is needed for Phase 2a trial.

Relevance 6/10Novelty 5/10Timing: today

Background

Filana Therapeutics (NASDAQ: FLNA) is a biotech developing simufilam for TSC‑related epilepsy. The 8‑K reports a new independent director and upcoming Phase 2a study.

Company-level read

Ticker impact

$FLNANeutralMedium confidence
Context

Filana Therapeutics filed an 8‑K announcing the appointment of Jill M. Quigley to its board of directors and upcoming Phase 2a trial plans.

Expected impact

likely slight upward pressure as investors value added governance experience

Evidence & confidence

New director with biotech financing background could improve execution of upcoming trial, but no immediate financial impact.

Market effects

Minor; adds credibility to a small‑cap biotech pursuing CNS trials.

Limited to US biotech investors.

Low; no broader market effect.

Counterpoint

Board change may not translate into near‑term price move; focus remains on trial data.

Key entities

  • Filana Therapeutics, Inc.

    NASDAQ‑listed biotech developing CNS therapies.

  • Jill M. Quigley

    New independent board member with biotech leadership experience.

Related articles

$FLNAMed

Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update – Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold – Recent publication in Cells 1 prov

$FLNAMedAI 8/10

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organizatio

$FLNAMed

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing